Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $2.6 million.

  • Utah Medical Products' Income towards Parent Company fell 2615.77% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 2383.01%. This contributed to the annual value of $13.5 million for FY2024, which is 1548.64% down from last year.
  • Utah Medical Products' Income towards Parent Company amounted to $2.6 million in Q3 2025, which was down 2615.77% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Utah Medical Products' Income towards Parent Company peaked at $4.3 million during Q4 2023, and registered a low of $2.6 million during Q3 2025.
  • In the last 5 years, Utah Medical Products' Income towards Parent Company had a median value of $3.9 million in 2023 and averaged $3.7 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 16092.92% in 2021, then plummeted by 3229.12% in 2024.
  • Utah Medical Products' Income towards Parent Company (Quarter) stood at $4.1 million in 2021, then fell by 0.56% to $4.1 million in 2022, then increased by 4.31% to $4.3 million in 2023, then plummeted by 32.29% to $2.9 million in 2024, then dropped by 9.34% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $3.0 million for Q2 2025, and $3.0 million during Q1 2025.